EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2

Irene Wanjiru Kiarie, Gyula Hoffka, Manon Laporte iD, Pieter Leyssen iD, Johan Neyts iD, József Tőzsér iD, Mohamed Mahdi iD

Viruses · 2024

DOI: 10.3390/v16101607 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Irene Wanjiru Kiarie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Retroviral Biochemistry, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, …. Hauptthemen laut MEDLINE: Raltegravir Potassium, HIV-2, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry for Innovation and Technology, New National Excellence Program of the Ministry of Culture and Innovation, ERINHA-Advance project (funding from the European Union's Horizon 2020 Research & Innovation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase. The viral capsid plays an important role during the viral life cycle, including nuclear importation in the case of lentiviruses and integration targeting events; hence, targeting the integrase and the viral capsid is a favorable therapeutic strategy. While integrase strand transfer inhibitors (INSTIs) are recommended as first-line regimens given their high efficacy and tolerability, lenacapavir is the first capsid inhibitor and the newest addition to the HIV treatment arsenal. These inhibitors are however designed for treatment of HIV-1 infection, and their efficacy against HIV-2 remains widely understudied and inconclusive, supported only by a few limited phenotypic susceptibility studies. We therefore carried out inhibition profiling of a panel of second-generation INSTIs and lenacapavir against HIV-2 in cell culture, utilizing pseudovirion inhibition profiling assays. Our results show that the tested INSTIs and lenacapavir exerted excellent efficacy against ROD-based HIV-2 integrase. We further evaluated the efficacy of raltegravir and other INSTIs against different variants of SARS-CoV-2; however, contrary to previous in silico findings, the inhibitors did not demonstrate significant antiviral activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Raltegravir PotassiumHIV-2SARS-CoV-2HumansHIV Integrase InhibitorsAntiviral AgentsHEK293 CellsCapsidHIV InfectionsHIV IntegraseCOVID-19 Drug TreatmentCell Line

Stichwörter der Autor:innen

HIVHIV-2SARS-CoV-2integraseintegrase strand transfer inhibitor (INSTIs)lenacapavir

Substanzen

Raltegravir PotassiumHIV Integrase InhibitorsAntiviral AgentsHIV Integrase

Autor:innen und Institutionen

  • Laboratory of Retroviral Biochemistry, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
  • Doctoral School of Molecular Cell and Immune Biology, University of Debrecen, 4032 Debrecen, Hungary.
  • Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.
  • European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Rue du Trône 98, 1050 Brussels, Belgium.

ORCID-Profile: Manon Laporte, Pieter Leyssen, Johan Neyts, József Tőzsér, Mohamed Mahdi

Förderung

  • Ministry for Innovation and Technology
  • New National Excellence Program of the Ministry of Culture and Innovation
  • ERINHA-Advance project (funding from the European Union's Horizon 2020 Research & Innovation Program
  • Ministry for Innovation and Technology in Hungary
  • ERINHA

Zitieren

APA

Kiarie, I. W., Hoffka, G., Laporte, M., Leyssen, P., Neyts, J., Tőzsér, J., & Mahdi, M. (2024). Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2. Viruses. https://doi.org/10.3390/v16101607

Vancouver

Kiarie IW, Hoffka G, Laporte M, Leyssen P, Neyts J, Tőzsér J, et al. Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2. Viruses. 2024. doi:10.3390/v16101607

BibTeX
@article{Kiarie2024,
  author = {Kiarie, Irene Wanjiru and Hoffka, Gyula and Laporte, Manon and Leyssen, Pieter and Neyts, Johan and Tőzsér, József and Mahdi, Mohamed},
  title = {Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16101607}
}
Kostenlos starten →